Meanwhile, high levels of MAPKAPK2 were positively correlated with poor prognosis of glioma patients with IDH mutant (mut) and 1p/19q non-codeletion gliomas but not in IDH wt and 1p/19q codeletion gliomas (Figures 3P–S). This evidence concerns the gene MAPKAPK2 and central nervous system cancer.